SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:lup.lub.lu.se:7ad9a57d-07a2-4df6-b9ca-559badb034ae"
 

Sökning: onr:"swepub:oai:lup.lub.lu.se:7ad9a57d-07a2-4df6-b9ca-559badb034ae" > Tolerance and effic...

  • Ekholm, S (författare)

Tolerance and efficacy of Omniscan (gadodiamide injection) in MR imaging of the central nervous system

  • Artikel/kapitelEngelska1996

Förlag, utgivningsår, omfång ...

  • 1996

Nummerbeteckningar

  • LIBRIS-ID:oai:lup.lub.lu.se:7ad9a57d-07a2-4df6-b9ca-559badb034ae
  • https://lup.lub.lu.se/record/1110458URI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:art swepub-publicationtype
  • Ämneskategori:ref swepub-contenttype

Anmärkningar

  • PURPOSE: This Swedish multicenter trial was performed on patients with known or suspected lesions of the CNS for which an MR examination using a contrast medium was indicated. A total of 8 MR centers participated in the study to establish the safety and efficacy of Omniscan (gadodiamide injection) in clinical routine using a standard dose of 0.1 mmol Gd/kg b.w. MATERIAL AND METHODS: Seven hundred adult patients who had been referred for MR investigation of suspected CNS lesions were included in the study. Since most patients were examined on an outpatient basis, it was decided to use an explicit questionnaire regarding adverse events that developed within 24 h after examination. The efficacy evaluation involved comparisons of detectability, delineation, and number of lesions before and after injection of Omniscan. RESULTS: No serious or unexpected adverse event was found. There were a total of 70 (10.2%) patients with adverse events, excluding those judged not to be contrast media-related. However, only 15 patients (2.2%) had adverse events that possibly or probably were related to the contrast medium. Usually, the symptoms were headache, dizziness, abnormal taste, and nausea. Two patients complained of itching, but only one developed urticaria. The efficacy was similar to that of other currently used Gd-based MR agents. Lesions were more often seen on T2-weighted images, but the contrast medium improved lesion delineation, contributing to higher certainty in diagnosis, and provided more confidence in excluding suspected abnormality. CONCLUSION: Omniscan was found to be a safe and clinically valuable contrast medium for MR imaging of the CNS.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Jonsson, E (författare)
  • Sandvik, L (författare)
  • Fagerlund, M (författare)
  • Holtås, StigLund University,Lunds universitet,Diagnostisk radiologi, Lund,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Diagnostic Radiology, (Lund),Section V,Department of Clinical Sciences, Lund,Faculty of Medicine(Swepub:lu)drad-sho (författare)
  • Isberg, B (författare)
  • Lindell, D (författare)
  • Linden, B (författare)
  • Sjöberg, S (författare)
  • Thuomas, K A (författare)
  • Tollesson, P O (författare)
  • Diagnostisk radiologi, LundSektion V (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Acta Radiologica37:2, s. 223-2281600-0455

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy